Short Interest in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Decreases By 74.2%

Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totaling 103,943 shares, a decrease of 74.2% from the November 30th total of 402,206 shares. Based on an average daily volume of 209,659 shares, the short-interest ratio is currently 0.5 days. Approximately 7.8% of the shares of the company are short sold. Approximately 7.8% of the shares of the company are short sold. Based on an average daily volume of 209,659 shares, the short-interest ratio is currently 0.5 days.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 30th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research report on Wednesday, October 8th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Galmed Pharmaceuticals has a consensus rating of “Reduce”.

Galmed Pharmaceuticals Price Performance

Shares of NASDAQ:GLMD traded up $0.01 during trading on Thursday, reaching $0.89. The stock had a trading volume of 29,664 shares, compared to its average volume of 160,569. The stock has a market capitalization of $1.46 million, a PE ratio of -2.77 and a beta of 0.31. Galmed Pharmaceuticals has a 52 week low of $0.74 and a 52 week high of $3.61. The business’s 50-day moving average price is $1.11 and its 200 day moving average price is $1.44.

Institutional Investors Weigh In On Galmed Pharmaceuticals

An institutional investor recently bought a new position in Galmed Pharmaceuticals stock. Two Sigma Investments LP bought a new position in shares of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 21,200 shares of the biopharmaceutical company’s stock, valued at approximately $29,000. Two Sigma Investments LP owned approximately 1.28% of Galmed Pharmaceuticals at the end of the most recent quarter. 76.14% of the stock is owned by institutional investors and hedge funds.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders.